In Elderly Patients With Antipsychotic-Induced Hyperprolactinemia, Could Switching to a Prolactin-Sparing Antipsychotic or Adding a Dopamine Agonist, Rather Than Maintaining the Current Regimen, Normalize the Prolactin Levels Without Triggering Psychotic Relapse or Increasing the Risk of Life-Threatening Adverse Events? A Systematic Review

Aims: Elevated prolactin levels due to antipsychotic drugs are prevalent in elderly patients and may cause multiple complications. Hence, the purpose of the present study is to compare the effectiveness of changing existing antipsychotic treatments with prolactin-sparing antipsychotics or adding dop...

Full description

Saved in:
Bibliographic Details
Main Authors: Gaurav Uppal, Sathyan Soundara Rajan, Akhila Bhandarkar, Sneh Babhulkar, Asha Devi Dhandapani
Format: Article
Language:English
Published: Cambridge University Press 2025-06-01
Series:BJPsych Open
Online Access:https://www.cambridge.org/core/product/identifier/S2056472425102366/type/journal_article
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850059345042079744
author Gaurav Uppal
Sathyan Soundara Rajan
Akhila Bhandarkar
Sneh Babhulkar
Asha Devi Dhandapani
author_facet Gaurav Uppal
Sathyan Soundara Rajan
Akhila Bhandarkar
Sneh Babhulkar
Asha Devi Dhandapani
author_sort Gaurav Uppal
collection DOAJ
description Aims: Elevated prolactin levels due to antipsychotic drugs are prevalent in elderly patients and may cause multiple complications. Hence, the purpose of the present study is to compare the effectiveness of changing existing antipsychotic treatments with prolactin-sparing antipsychotics or adding dopaminergic agents to the existing treatment in patients with clinically insignificant hyperprolactinaemia in later life.
format Article
id doaj-art-e8aca0797f2f4833944fe148f6dec2b0
institution DOAJ
issn 2056-4724
language English
publishDate 2025-06-01
publisher Cambridge University Press
record_format Article
series BJPsych Open
spelling doaj-art-e8aca0797f2f4833944fe148f6dec2b02025-08-20T02:50:55ZengCambridge University PressBJPsych Open2056-47242025-06-0111S72S7210.1192/bjo.2025.10236In Elderly Patients With Antipsychotic-Induced Hyperprolactinemia, Could Switching to a Prolactin-Sparing Antipsychotic or Adding a Dopamine Agonist, Rather Than Maintaining the Current Regimen, Normalize the Prolactin Levels Without Triggering Psychotic Relapse or Increasing the Risk of Life-Threatening Adverse Events? A Systematic ReviewGaurav Uppal0Sathyan Soundara Rajan1Akhila Bhandarkar2Sneh Babhulkar3Asha Devi Dhandapani4Satyam Hospital, Ludhiana, IndiaBCUHB, Wrexham, United KingdomKSHEMA, Mangalore, IndiaGreater Glasgow and Clyde NHS Trust, Glasgow, United KingdomBCUHB, Wrexham, United KingdomAims: Elevated prolactin levels due to antipsychotic drugs are prevalent in elderly patients and may cause multiple complications. Hence, the purpose of the present study is to compare the effectiveness of changing existing antipsychotic treatments with prolactin-sparing antipsychotics or adding dopaminergic agents to the existing treatment in patients with clinically insignificant hyperprolactinaemia in later life.https://www.cambridge.org/core/product/identifier/S2056472425102366/type/journal_article
spellingShingle Gaurav Uppal
Sathyan Soundara Rajan
Akhila Bhandarkar
Sneh Babhulkar
Asha Devi Dhandapani
In Elderly Patients With Antipsychotic-Induced Hyperprolactinemia, Could Switching to a Prolactin-Sparing Antipsychotic or Adding a Dopamine Agonist, Rather Than Maintaining the Current Regimen, Normalize the Prolactin Levels Without Triggering Psychotic Relapse or Increasing the Risk of Life-Threatening Adverse Events? A Systematic Review
BJPsych Open
title In Elderly Patients With Antipsychotic-Induced Hyperprolactinemia, Could Switching to a Prolactin-Sparing Antipsychotic or Adding a Dopamine Agonist, Rather Than Maintaining the Current Regimen, Normalize the Prolactin Levels Without Triggering Psychotic Relapse or Increasing the Risk of Life-Threatening Adverse Events? A Systematic Review
title_full In Elderly Patients With Antipsychotic-Induced Hyperprolactinemia, Could Switching to a Prolactin-Sparing Antipsychotic or Adding a Dopamine Agonist, Rather Than Maintaining the Current Regimen, Normalize the Prolactin Levels Without Triggering Psychotic Relapse or Increasing the Risk of Life-Threatening Adverse Events? A Systematic Review
title_fullStr In Elderly Patients With Antipsychotic-Induced Hyperprolactinemia, Could Switching to a Prolactin-Sparing Antipsychotic or Adding a Dopamine Agonist, Rather Than Maintaining the Current Regimen, Normalize the Prolactin Levels Without Triggering Psychotic Relapse or Increasing the Risk of Life-Threatening Adverse Events? A Systematic Review
title_full_unstemmed In Elderly Patients With Antipsychotic-Induced Hyperprolactinemia, Could Switching to a Prolactin-Sparing Antipsychotic or Adding a Dopamine Agonist, Rather Than Maintaining the Current Regimen, Normalize the Prolactin Levels Without Triggering Psychotic Relapse or Increasing the Risk of Life-Threatening Adverse Events? A Systematic Review
title_short In Elderly Patients With Antipsychotic-Induced Hyperprolactinemia, Could Switching to a Prolactin-Sparing Antipsychotic or Adding a Dopamine Agonist, Rather Than Maintaining the Current Regimen, Normalize the Prolactin Levels Without Triggering Psychotic Relapse or Increasing the Risk of Life-Threatening Adverse Events? A Systematic Review
title_sort in elderly patients with antipsychotic induced hyperprolactinemia could switching to a prolactin sparing antipsychotic or adding a dopamine agonist rather than maintaining the current regimen normalize the prolactin levels without triggering psychotic relapse or increasing the risk of life threatening adverse events a systematic review
url https://www.cambridge.org/core/product/identifier/S2056472425102366/type/journal_article
work_keys_str_mv AT gauravuppal inelderlypatientswithantipsychoticinducedhyperprolactinemiacouldswitchingtoaprolactinsparingantipsychoticoraddingadopamineagonistratherthanmaintainingthecurrentregimennormalizetheprolactinlevelswithouttriggeringpsychoticrelapseorincreasingtheriskoflifethr
AT sathyansoundararajan inelderlypatientswithantipsychoticinducedhyperprolactinemiacouldswitchingtoaprolactinsparingantipsychoticoraddingadopamineagonistratherthanmaintainingthecurrentregimennormalizetheprolactinlevelswithouttriggeringpsychoticrelapseorincreasingtheriskoflifethr
AT akhilabhandarkar inelderlypatientswithantipsychoticinducedhyperprolactinemiacouldswitchingtoaprolactinsparingantipsychoticoraddingadopamineagonistratherthanmaintainingthecurrentregimennormalizetheprolactinlevelswithouttriggeringpsychoticrelapseorincreasingtheriskoflifethr
AT snehbabhulkar inelderlypatientswithantipsychoticinducedhyperprolactinemiacouldswitchingtoaprolactinsparingantipsychoticoraddingadopamineagonistratherthanmaintainingthecurrentregimennormalizetheprolactinlevelswithouttriggeringpsychoticrelapseorincreasingtheriskoflifethr
AT ashadevidhandapani inelderlypatientswithantipsychoticinducedhyperprolactinemiacouldswitchingtoaprolactinsparingantipsychoticoraddingadopamineagonistratherthanmaintainingthecurrentregimennormalizetheprolactinlevelswithouttriggeringpsychoticrelapseorincreasingtheriskoflifethr